Ajanta Pharma Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Ajanta Pharma heeft een totaal eigen vermogen van ₹36.8B en een totale schuld van ₹24.2M, wat de schuld-eigenvermogensverhouding op 0.07% brengt. De totale activa en totale passiva bedragen respectievelijk ₹47.9B en ₹11.1B. De EBIT Ajanta Pharma is ₹11.3B waardoor de rentedekking -66.7 is. Het heeft contanten en kortetermijnbeleggingen van ₹7.4B.
Belangrijke informatie
0.07%
Verhouding schuld/eigen vermogen
₹24.20m
Schuld
| Rente dekkingsratio | -66.7x |
| Contant | ₹7.42b |
| Aandelen | ₹36.77b |
| Totaal verplichtingen | ₹11.14b |
| Totaal activa | ₹47.91b |
Recente financiële gezondheidsupdates
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Aug 23
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Recent updates
Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Oct 31Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Sep 10We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Aug 23Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 04Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E
Aug 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Jun 01Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price
Apr 05We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
Dec 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Oct 24Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Aug 25Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?
Jul 19A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Apr 28Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut
Feb 06Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Dec 13Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50
Oct 31Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching
Sep 22Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?
Sep 08Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet
Jul 07Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?
Jun 14Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?
May 15Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 10Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 11Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?
Feb 24The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On
Jan 30
What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?
Jan 18Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Jan 06Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ₹27.9B ) AJANTPHARM } overtreffen de korte termijn passiva ( ₹9.1B ).
Langlopende schulden: De kortetermijnactiva AJANTPHARM ( ₹27.9B ) overtreffen de langetermijnschulden ( ₹2.0B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: AJANTPHARM heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van AJANTPHARM is de afgelopen 5 jaar gedaald van 1.6% naar 0.07%.
Schuldendekking: De schuld van AJANTPHARM wordt goed gedekt door de operationele kasstroom ( 48037.2% ).
Rentedekking: AJANTPHARM verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.